What does PHARMA4L do?

PHARMA4L is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 12 July 2016, 1 establishment.

What is the address of PHARMA4L?

The registered office of PHARMA4L is located at Sint - Jansdreef 18, 9900 Eeklo.

Is PHARMA4L still active?

Yes. According to the CBE (28 September 2026) PHARMA4L is active, legal situation “Normale toestand”, started on 12 July 2016.

Is PHARMA4L registered on Peppol?

Yes, PHARMA4L is registered on the Peppol network with ID 0208:0658939608.

What is the enterprise number of PHARMA4L?

The enterprise number of PHARMA4L is BE0658939608.

When was PHARMA4L founded?

PHARMA4L was founded on 12 July 2016.

Who are the directors of PHARMA4L?

According to the 2025 annual accounts, the directors of PHARMA4L are: Bernard Brondel.

Is PHARMA4L a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 July 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMA4L make in 2025?

PHARMA4L posted a profit after taxes of € 242,951 in financial year 2025.

What is the revenue of PHARMA4L?

As a small company, PHARMA4L is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 168,584.

PHARMA4L (Private Limited) - Eeklo - BE0658939608

Dossier PHARMA4L, printed on 28 September 2026 from databakkes.be/en/0658939608/pharma4l. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 25 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMA4L from Eeklo, company number BE0658939608, closed financial year 2025 with a result of € 242,951 after tax. For that financial year PHARMA4L recorded a gross margin of € 168,584 and equity of € 1.4 million. Compared with financial year 2024, the result moved from € 192,196 to € 242,951. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 1.4 million

▲ 22% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 242,951

▲ 26% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 18,638

▼ 51% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.3 million.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 330,273

▼ 23% vs 2024

€ 112,043 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 23,162

▲ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 38,915

▲ 53% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 129,591 Gross margin 2022: € 129,591 First fiscal year in the series	€ 129,033 Gross margin 2023: € 129,033 Unchanged (€ 129,591) Unfavourable step	€ 121,552 Gross margin 2024: € 121,552 ▼ 6% vs 2023 (€ 129,033) Unfavourable step	€ 168,584 Gross margin 2025: € 168,584 ▲ 39% vs 2024 (€ 121,552) Favourable step	▲ 39%
Profit after taxes	€ 228,524 Profit after taxes 2022: € 228,524 First fiscal year in the series	€ 78,407 Profit after taxes 2023: € 78,407 ▼ 66% vs 2022 (€ 228,524) Unfavourable step	€ 192,196 Profit after taxes 2024: € 192,196 ▲ 145% vs 2023 (€ 78,407) Favourable step	€ 242,951 Profit after taxes 2025: € 242,951 ▲ 26% vs 2024 (€ 192,196) Favourable step	▲ 26%
Equity	€ 842,710 Equity 2022: € 842,710 First fiscal year in the series	€ 921,117 Equity 2023: € 921,117 ▲ 9% vs 2022 (€ 842,710) Favourable step	€ 1,113,313 Equity 2024: € 1,113,313 ▲ 21% vs 2023 (€ 921,117) Favourable step	€ 1,356,264 Equity 2025: € 1,356,264 ▲ 22% vs 2024 (€ 1,113,313) Favourable step	▲ 22%
Total debts	€ 1,010,078 Total debts 2022: € 1,010,078 First fiscal year in the series	€ 904,079 Total debts 2023: € 904,079 ▼ 10% vs 2022 (€ 1,010,078) Favourable step	€ 724,363 Total debts 2024: € 724,363 ▼ 20% vs 2023 (€ 904,079) Favourable step	€ 780,764 Total debts 2025: € 780,764 ▲ 8% vs 2024 (€ 724,363) Unfavourable step	▲ 8%
Cash	€ 73,077 Cash 2022: € 73,077 First fiscal year in the series	€ 29,513 Cash 2023: € 29,513 ▼ 60% vs 2022 (€ 73,077) Unfavourable step	€ 38,322 Cash 2024: € 38,322 ▲ 30% vs 2023 (€ 29,513) Favourable step	€ 18,638 Cash 2025: € 18,638 ▼ 51% vs 2024 (€ 38,322) Unfavourable step	▼ 51%
Land & buildings	-	-	-	€ 264,493 Land & buildings 2025: € 264,493 First fiscal year in the series
Retained profit	€ 792,710 Retained profit 2022: € 792,710 First fiscal year in the series	€ 871,117 Retained profit 2023: € 871,117 ▲ 10% vs 2022 (€ 792,710) Favourable step	€ 1,063,313 Retained profit 2024: € 1,063,313 ▲ 22% vs 2023 (€ 871,117) Favourable step	€ 1,306,264 Retained profit 2025: € 1,306,264 ▲ 23% vs 2024 (€ 1,063,313) Favourable step	▲ 23%
Bank debt	€ 667,016 Bank debt 2022: € 667,016 First fiscal year in the series	€ 545,090 Bank debt 2023: € 545,090 ▼ 18% vs 2022 (€ 667,016) Favourable step	€ 431,192 Bank debt 2024: € 431,192 ▼ 21% vs 2023 (€ 545,090) Favourable step	€ 330,273 Bank debt 2025: € 330,273 ▼ 23% vs 2024 (€ 431,192) Favourable step	▼ 23%
Balance sheet total	€ 1,852,788 Balance sheet total 2022: € 1,852,788 First fiscal year in the series	€ 1,825,196 Balance sheet total 2023: € 1,825,196 ▼ 1% vs 2022 (€ 1,852,788) Unchanged	€ 1,837,677 Balance sheet total 2024: € 1,837,677 ▲ 1% vs 2023 (€ 1,825,196) Unchanged	€ 2,137,029 Balance sheet total 2025: € 2,137,029 ▲ 16% vs 2024 (€ 1,837,677) Unchanged	▲ 16%

Key figures of PHARMA4L, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA4L?

What happened at PHARMA4L in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 242,951 (▲ 26% vs 2024). filed late Source: NBB ↗
Aug 18, 2016 New establishment in Eeklo. KBO
Jul 12, 2016 Start of the company according to the CBE. KBO

In short

From € 228,524 profit in 2022 to € 242,951 profit in 2025.

Paid € 152,208 in corporate taxes since 2022.

Best year ever: 2025, with € 242,951 profit.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMA4L? We notify you, reason included.

Follow PHARMA4L

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Bernard Brondel

PHARMA4L

Brondel Apotheek 100%

Behind PHARMA4L is Bernard Brondel. It owns 100% of Brondel Apotheek itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Bernard Brondel

Director

Also active at: APOTHEEK BRONDEL, Care4L

Establishments

Establishment units

Physical locations of this company

Registered office

Sint - Jansdreef 18

9900 Eeklo

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0658.939.608

VAT number

BE 0658.939.608

Registered office

Sint - Jansdreef 18, 9900 Eeklo

Names & denominations

PHARMA4L

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

12 July 2016

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA4L

Warning lights

Financials

What happened to PHARMA4L?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions